The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Open accessAbstract
OBJECTIVES: The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD). METHODS: We prospectively evaluated CD patients enrolled in the large, observational Crohn's Therapy, Resource, Evaluation, and Assessment Tool registry, established to compare infliximab safety with conventional nonbiological medications in CD. RESULTS: A total of 6,273 patients were enrolled and evaluated on or before 23 February 2010; 3,420 received infliximab (17,712 patient-years; 89.9% received ≥ 2 infusions) and 2,853 received other-treatments-only (13,251 patient-years). Mean length of patient follow-up was 5.2 years. More infliximab- than other-treatments-only-treated patients had moderate-to-severe (30.6% vs. 10.7%) or severe-to-fulminant (2.5% vs. 0.6%) disease severity (P < 0.001). In the year before enrollment, more infliximab- than other-treatments-only-treated patients required surgical intervention (17.4% vs. 13.6%), medical hospitalization (14.2% vs. 8.8%), prednisone (47.8% vs. 31.4%), immunomodulators (52.0% vs. 32.1%), and narcotic analgesics (17.3% vs. 9.1%). Patient mortality was similar for infliximab- and other-treatments-only-treated patients (0.58 vs. 0.59/100 patient-years). In multivariate logistic regression analyses, treatment with prednisone (hazard ratio (HR) = 2.14, 95% confidence interval (CI) = 1.55, 2.95; P < 0.001) or narcotic analgesics (HR = 1.79, 95% CI = 1.29, 2.48; P < 0.001) and age (HR = 1.08, 95% CI = 1.07, 1.09; P < 0.001) were associated with increased mortality risk. Neither infliximab nor immunomodulator treatment was associated with increased mortality risk. Factors independently associated with serious infections included moderate-to-severe disease activity (HR = 2.24, 95% CI = 1.57, 3.19; P < 0.001), narcotic analgesic treatment (HR = 1.98, 95% CI = 1.44, 2.73; P < 0.001), prednisone therapy (HR = 1.57, 95% CI = 1.17, 2.10; P = 0.002), and infliximab treatment (HR = 1.43, 95% CI = 1.11, 1.84; P = 0.006). CONCLUSIONS: Mortality was similar between infliximab- and other-treatments-only-treated CD patients. An increased risk of serious infection with infliximab was observed, although CD severity and use of prednisone or narcotic analgesics carried higher risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationPodolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,159
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationManagement of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Self-citationSerious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.002 · Cited by 905
Self-citationCrohn's disease in Olmsted County, Minnesota, 1940–1993: Incidence, prevalence, and survival
Loftus, E. V., Silverstein, M. D., Sandborn, W. J., Tremaine, W. J., Harmsen, W. S., & Zinsmeister, A. R. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70421-4 · Cited by 623
Self-citationKotlyar, D. S., Osterman, M. T., Diamond, R. H., Porter, D., Blonski, W. C., Wasik, M., Sampat, S., Mendizabal, M., Lin, M. V., & Lichtenstein, G. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.016 · Cited by 477
Self-citationLong-term follow-up of patients with Crohn's disease
Farmer, R. G., Whelan, G., & Fazio, V. W. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90006-x · Cited by 440
Long-term follow-up of patients with Crohn's disease
Ricketts, R. R. (1986) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(86)80458-4 · Cited by 395
Survival and causes of death in patients with inflammatory bowel disease: A population-based study
Ekbom, A., Helmick, C. G., Zack, M., Holmberg, L., & Adami, H.-O. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90029-x · Cited by 265
Management of Crohn's disease in adults
Hanauer, S. B., Sandborn, W., & The Practice Parameters Committee of the American College of Gastroenterology (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03671.x · Cited by 261
Self-citationJess, T., Winther, K. V., Munkholm, P., Langholz, E., & Binder, V. (2002) · Gastroenterology · doi:10.1053/gast.2002.33632 · Cited by 191
INFECTIONS ASSOCIATED WITH STEROID USE
Klein, N. C., Go, C. H.-U., & Cunha, B. A. (2001) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70154-9 · Cited by 176
How do patients with inflammatory bowel disease want their biological therapy administered?
Allen, P. B., Lindsay, H., & Tham, T. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-1 · Cited by 127
Adalimumab safety in global clinical trials of patients with Crohnʼs disease
Colombel, J., Sandborn, W. J., Panaccione, R., Robinson, A. M., Lau, W., Li, J., & Cardoso, A. T. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20956 · Cited by 127
Self-citationSafety of anti-tumor necrosis factor therapy in inflammatory bowel disease
Hoentjen, F., & Bodegraven, A. A. V. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2067 · Cited by 115
Glucocorticoids in the treatment of early and late RA
Bijlsma, J. W. J., Boers, M., Saag, K. G., & Furst, D. E. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.11.1033 · Cited by 101
Loftus, E. V., Silverstein, M. D., Sandborn, W. J., Tremaine, W., Harmsen, W. S., & ZINSMEISTER, A. R. (1999) · Gastroenterology · Cited by 76
Self-citationOussalah, A., Danese, S., & Peyrin‐Biroulet, L. (2010) · Current Drug Targets · doi:10.2174/138945010790309939 · Cited by 45
Management of inflammatory bowel disease.
Botoman, V. A., Bonner, G. F., & Botoman, D. A. (1998) · PubMed · Cited by 45
What is the optimal therapy for Crohn’s disease: step-up or top-down?
Lin, M. V., Blonski, W. C., & Lichtenstein, G. R. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.4 · Cited by 44
Self-citationLichtenstein, G. R. (2010) · PubMed Central · Cited by 26
Self-citationConcomitant Use of Immunomodulators with Anti-TNF in Crohns Disease: Yes or No?
Meier, J., & Sturm, A. (2010) · Current Drug Targets · doi:10.2174/138945010790309948 · Cited by 10
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Self-citationConsensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J.-F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 806
Self-citation
Metadata
- Authors
- Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Price, S., Langholff, W., Londhe, A., & Sandborn, W. J.
- Venue
- American Journal of Gastroenterology
- Published
- 2012-09
- Volume
- 107
- Issue
- 9
- Pages
- 1409-1422
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1989167852
- Cited by
- 791
- References
- 23
- FWCI
- 33.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.